B
Bertrand Godeau
Researcher at Paris 12 Val de Marne University
Publications - 108
Citations - 2120
Bertrand Godeau is an academic researcher from Paris 12 Val de Marne University. The author has contributed to research in topics: Rituximab & Romiplostim. The author has an hindex of 17, co-authored 108 publications receiving 1814 citations.
Papers
More filters
Journal ArticleDOI
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.
Matthieu Mahevas,Viet-Thi Tran,Mathilde Roumier,Amélie Chabrol,Romain Paule,Constance Guillaud,Elena Fois,Raphaël Lepeule,Tali Anne Szwebel,François Xavier Lescure,Frédéric Schlemmer,Marie Matignon,Mehdi Khellaf,Etienne Crickx,Benjamin Terrier,Caroline Morbieu,Paul Legendre,Julien Dang,Yoland Schoindre,Jean-Michel Pawlotsky,Marc Michel,Elodie Perrodeau,Nicolas Carlier,Nicolas Roche,Victoire de Lastours,Clément Ourghanlian,Solen Kernéis,Philippe Ménager,Luc Mouthon,Etienne Audureau,Philippe Ravaud,Bertrand Godeau,S. Gallien,Nathalie Costedoat-Chalumeau +33 more
TL;DR: Hydxychloroquine has received worldwide attention as a potential treatment for covid-19 because of positive results from small studies, but the results of this study do not support its use in patients admitted to hospital with covids-19 who require oxygen.
Journal ArticleDOI
The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases
Marc Michel,Valérie Chanet,Agnès Dechartres,Anne-Sophie Morin,Jean-Charles Piette,Lorenzo Cirasino,Giovanni Emilia,Francesco Zaja,Marco Ruggeri,Emmanuel Andrès,Philippe Bierling,Bertrand Godeau,Francesco Rodeghiero +12 more
TL;DR: In elderly patients, the risk of cardiovascular manifestations related to AIHA seems to be higher than the ITP-related risk of severe bleeding, and in elderly patients who are in remission off treatment, ES is a potentially life-threatening condition that may be associated with other underlying autoimmune or lymphoproliferative disorders.
Journal ArticleDOI
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment
TL;DR: Treatment for primary immune thrombocytopenia in adults has changed with the advent of rituximab and TPO-RAs and its outcome is currently unpredictable, leading some physicians and patients toward postponement and use of alternative approaches.
Journal ArticleDOI
Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides.
M. Gayraud,Loïc Guillevin,Pascal Cohen,F. Lhote,Patrice Cacoub,P Deblois,Bertrand Godeau,M Ruel,Elisabeth Vidal,M Piontud,J.-P. Ducroix,S Lassoued,B Christoforov,P Babinet +13 more
TL;DR: No superiority in terms of efficacy could be established between the two regimens; however, the number of patients included was too small to conclude definitively and the high number of adverse effects leads us to recommend pulse over oral CY and an overall lowering of the doses of immunosuppression.
Journal ArticleDOI
Thrombopoietin receptor agonists: ten years later
TL;DR: This summary review on TPO-RA will summarize what is known regarding efficacy in ITP, evaluate safety concerns in more depth, and focus on the questions that remain.